SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (10365)2/9/2004 12:11:01 PM
From: tom pope  Respond to of 52153
 
I saw that too, and the only thing I could think of is that MSHL is VERY thinly traded. Float is only 2MM shares per yahoo



To: quidditch who wrote (10365)2/9/2004 1:06:26 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
quid,

NVGN owns 90% of MSHL. MSHL has all the rights to this drug, and is the more leveraged play on the drug. But as others have said, MSHL is a recent IPO and is very thinly traded indeed.

(I personally own more NVGN than MSHL - the latter is a very high risk/high reward play).

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News